News

Home/News
News 2017-06-21T13:15:59+00:00
September 28, 2017
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
TEL AVIV, Israel, and SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD) and Arcturus Therapeutics, Inc., a privately held biotechnology company developing ...
September 28, 2017
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with ...
September 28, 2017
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
PARIS, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development ...
September 28, 2017
VBL Therapeutics to Present at the Chardan Gene Therapy Conference
TEL AVIV, Israel, Sept. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
September 28, 2017
CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease ...
September 28, 2017
Albireo Elects Roger Jeffs to Board of Directors
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 28, 2017
Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
September 28, 2017
Rockwell Files Calcitriol Post-Approval Manufacturing Submission with FDA
WIXOM, Mich., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), today provided an update on the commercial launch of Calcitriol, stating that it ...
September 27, 2017
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment ...
September 27, 2017
Kiadis Pharma Provides Update on the Marketing Authorization Application Process for ATIR101™ in Europe
AMSTERDAM-DUIVENDRECHT, The Netherlands -- Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to ...
September 27, 2017
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
September 27, 2017
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 27, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
September 27, 2017
Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
ENGLEWOOD CLIFFS, N.J. -- (BUSINESS WIRE) -- Immune Pharmaceuticals, Inc. (IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, ...
September 27, 2017
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, ...
September 27, 2017
Bellerophon Announces $23 Million Private Placement
WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities ...
September 27, 2017
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
BROOKLYN, N.Y., Sept. 27, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc.(AZRX) (“AzurRx” or the “Company”), today provided an update on the first six treated patients ...
September 26, 2017
TherapeuticsMD Announces Pricing of Common Stock Offering
BOCA RATON, Fla. -- (BUSINESS WIRE) -- TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the pricing of an underwritten public offering of 12.4 million shares of ...
September 26, 2017
BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced ...
September 26, 2017
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
MONMOUTH JUNCTION, N.J., Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ...
September 26, 2017
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
GENEVA & NANTES, France -- (BUSINESS WIRE) -- Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of two commercial license ...
Page 5 of 33